Company: SCLXW
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047800
Chunk: 45

Company: Scilex Holding Co
Filing Date: 2025-03-31
Form: 10-K
Item: Item 7
Chunk 45
---

    )

    SP-104

    Contracted R&D

    50

    925

    (875
    )

    Personnel

    292

    605

    (313
    )

    Other

    —

    149

    (149
    )

    Total SP-104

    342

    1,679

    (1,337
    )

    GLOPERBA

    Contracted R&D

    687

    345

    342

    Personnel

    813

    658

    155

    Other

    116

    115

    1

    Total GLOPERBA

    1,616

    1,118

    498

    ELYXYB

    Contracted R&D

    758

    1,252

    (494
    )

    Personnel

    1,068

    908

    160

    Other

    196

    391

    (195
    )

    Total ELYXYB

    2,022

    2,551

    (529
    )

    Total Research and Development Expenses
     
    $
    9,641

    $
    12,746

    $
    (3,105
    )

Research and development expenses for the years ended December 31, 2024 and 2023 were $9.6 million and $12.7 million, respectively. The $3.1 million decrease was primarily attributed to reduced costs of SP-103 due to the completion of the Phase 2 clinical study and reduced development costs of SP-104.

Selling, General and Administrative Expenses

Selling, general and administrative expenses for the years ended December 31, 2024 and 2023 were $119.0 million and $119.6 million, respectively. The decrease of approximately $0.6 million was primarily due to a $10.1 million decrease in legal fees, a $1.6 million decrease in insurance costs, a $0.4 million decrease in advisory and financing expenses and a $0.2 million decrease as a result of a $1.4 million decrease related to allowance for credit losses that was made in March 2023 for the receivable from Sorrento offset by a $1.2 million increase related to allowances for expected credit losses on accounts receivable, partially offset by a